Outstanding Control in Difficult to Control Diabetes
COMPOSITION: Pioglitazone HCI I.P. 15 mg
- A drug that lowers the level of glucose in the blood by reducing the production and secretion of glucose into the blood by the liver.
- Helps to lower blood glucose levels by increasing the sensitivity of liver, fat and muscle cells, to insulin.
- Improved insulin resistance and glycemic control, as well as TG and high-density lipoprotein-cholesterol [HDL-C] and may help reduce cardiovascular risk for patients with type-II diabetes.
- Pretreatment with Pioglitazone in diabetic patients with acute myocardial infarction (AMI) resulted in better myocardial perfusion with less reperfusion injury.
- Significantly reduced carotid and coronary atherosclerosis compared with the sulphonylurea glimepiride.
- Prodeced good glycemic control in Japanese patients with type-II diabetes, and significantly fewer patients treated with pioglitazone needed long-term insulin therapy.
- Type-II Diabates Mellitus
- Coronary Atherosclerosis
- Drug class: Thiazolidinediones
- Shows glycaemic control by improving insulin sensitivity through its action at PPAR gamma 1 and PPAR gamma.
- Increases glucose uptake and utilization in the peripheral organs and decreases gluconeogenesis in the liver.
- Acts by improving hyperinsulinemia, visceral obesity, hyperglycemia, hypertension, and risk factors involved in endothelial dysfunction, inflammation, and atherosclerosis.
- Reduces insulin resistance more than metformin.